课题基金 / 基金详情

COVID-19 RELATED STUDY INVOLVING DOGS

COVID-19 RELATED STUDY INVOLVING DOGS
涉及狗的 COVID-19 相关研究
批准号:
10269151
负责人:
DAVID MCCORMICK
金额:
$59.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-16 至 2021-03-15

项目摘要

项目成果

DAVID MCCORMICK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Human recombinant ACE2 will be administered to dogs as an aerosol to assess potential toxicities. Results will be used to support an Investigational New Drug Application with the FDA for a clinical trial addressing patients with COVID-19 infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013
  • 批准号:
    10932479
  • 项目类别:
  • 资助金额:
    $65.95万
  • 财政年份:
    2023
  • 负责人:
    DAVID MCCORMICK
  • 依托单位:
CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIO
  • 批准号:
    10710462
  • 项目类别:
  • 资助金额:
    $0.3万
  • 财政年份:
    2022
  • 负责人:
    DAVID MCCORMICK
  • 依托单位:
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
  • 批准号:
    10802090
  • 项目类别:
  • 资助金额:
    $145.68万
  • 财政年份:
    2022
  • 负责人:
    DAVID MCCORMICK
  • 依托单位:
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
  • 批准号:
    10605054
  • 项目类别:
  • 资助金额:
    $75.0万
  • 财政年份:
    2022
  • 负责人:
    DAVID MCCORMICK
  • 依托单位:
海外基金